Octapharma USA today announced the U.S. Food and Drug Administration (FDA) has approved WILATE® for treatment of adults and adolescents with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes and on demand treatment and control of bleeding episodes.
MedicaSafe, Inc. today announced a partnership with Amneal Pharmaceuticals, Inc. (NYSE: AMRX) to provide Amneal’s generic version of Suboxone® (buprenorphine and naloxone) as part of MedicaSafe’s data-generating medication system.
DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced..
ACell, Inc. today announced the launch of their new product, Gentrix® Hiatal at the 2019 Society of Laparoendoscopic Surgeons (SLS) Minimally Invasive Surgery Week 2019 (MISWeek 2019) in New Orleans, Louisiana.
Abiomed announces today that the Impella CP® with SmartAssist technology, which is designed to improve patient outcomes with advanced algorithms and simplified patient management, will be commercially available in Europe beginning at the European Society of Cardiology (ESC) Congress 2019 through a controlled roll out process at select sites.
W. L. Gore & Associates, Inc. (Gore) today announced that the U.S. Food and Drug Administration (FDA) has granted regulatory approval for commercial distribution for the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System..
Gecko Biomedical, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, has announced it will change the company name to TISSIUM as part of an overall rebranding of the company.
Chiropractors and even some medical doctors are now running scams where they claim that fetal birth products like amniotic fluid (i.e. baby urine), placental, umbilical, and Wharton's jelly contains millions of live fetal stem cells.
Vytronus, Inc., a privately held medical device company developing novel technologies for the treatment of cardiac arrhythmias, announced today that its early feasibility study of automated ultrasound technology for the treatment of persistent atrial fibrillation recently passed the midpoint in patient enrollment and is on track for completion of enrollment in mid-2019.
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced it has received CE Mark for Ortho's VITROS® XT MicroSlide, a new multi-test technology that allows labs to run two tests simultaneously.